4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / DOSE Trial of Opioid Sparing Effect (DOSE)

DOSE Trial of Opioid Sparing Effect (DOSE)

Study Description
Brief Summary:

Multicenter, double blind randomized controlled trial of fentanyl vs. fentanyl + dexmedetomidine as the initial regimen for maintenance of sedation in mechanically-ventilated, critically ill children.

This trial will evaluate the opioid-sparing effect of dexmedetomidine when administered with fentanyl to mechanically ventilated, critically ill children. Study drug or placebo will be administered with fentanyl, which will be titrated to achieve sedation scores consistent with response to light touch. Plasma samples and bedside assessments for pain, sedation, and delirium will be collected.


Condition or disease Intervention/treatment Phase
Dexmedetomidine Mechanical Ventilation Complication Critically Ill Drug: Fentanyl Drug: Dexmedetomidine Phase 1

Detailed Description:

Phase 1b randomized, double-blind, placebo-controlled dose escalation trial of sedation regimens in critically ill children. Testing the hypothesis of mean daily fentanyl dose through day 7 of mechanical ventilation will be reduced by ≥25% by the addition of dexmedetomidine to fentanyl therapy. This trial will involve multiple clinical sites. Randomization will occur by individual and investigators will be blinded to study/treatment arm. The statistical analysis will account for center effects, participant characteristics (including post-surgical state), and changes over time to minimize bias. In addition, PIs and study coordinators will undergo training to standardize assessment procedures. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); and, Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).

An interim analysis is planned for this trial.

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Phase 1b randomized, double-blind, placebo-controlled dose escalation trial. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: DEXMEDETOMIDINE OPIOID SPARING EFFECT IN MECHANICALLY VENTILATED CHILDREN: Phase 1b, Multicenter, Double Blind Randomized Controlled Dose Escalating Trial of Fentanyl vs. Fentanyl + Dexmedetomidine as the Initial Regimen for Maintenance of Sedation in Mechanically-ventilated, Critically Ill Children
Actual Study Start Date : July 18, 2019
Actual Primary Completion Date : October 21, 2020
Actual Study Completion Date : November 6, 2020
Arms and Interventions
Arm Intervention/treatment
Placebo Comparator: Fen. SOC+saline placebo (bolus+infusion)
Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
Drug: Fentanyl
Fentanyl standard of care

Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)
Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
Drug: Fentanyl
Fentanyl standard of care

Drug: Dexmedetomidine
Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)

Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)
Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
Drug: Fentanyl
Fentanyl standard of care

Drug: Dexmedetomidine
Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)

Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)
Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
Drug: Fentanyl
Fentanyl standard of care

Drug: Dexmedetomidine
Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)

Outcome Measures
Primary Outcome Measures :
  1. Mean daily dose of fentanyl in mcg/kg [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the opioid-sparing effect of dexmedetomidine when co-administered with fentanyl in children receiving mechanical ventilation. Characterization of differences between dosing exposures for the four groups will allow estimation of the opioid-sparing effect of dexmedetomidine.


Secondary Outcome Measures :
  1. Sedation based on the State Behavior Scale (SBS) relative to Fentanyl plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  2. Sedation based on SBS scale relative to Fentanyl plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  3. Sedation based on SBS scale relative to Fentanyl plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  4. Sedation based on SBS scale relative to Fentanyl plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  5. Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  6. Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  7. Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  8. Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.

  9. Sedation based on Richmond Agitation and Sedation Scale (RASS) scale relative to Fentanyl plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  10. Sedation based on RASS scale relative to Fentanyl plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-pint scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  11. Sedation based on RASS scale relative to Fentanyl plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  12. Sedation based on RASS scale relative to Fentanyl plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  13. Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  14. Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  15. Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  16. Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.

  17. Incidence of SAEs in subjects [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).

  18. Number of clinically significant episodes of hypotension [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).

  19. Number of clinically significant episodes of bradycardia [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).

  20. Number of clinically significant episodes of urinary retention [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).


Other Outcome Measures:
  1. Average daily Cornell Assessment of Pediatrics in Delirium (CAPD) scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.

  2. Maximum daily CAPD scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.

  3. Minimum daily CAPD scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.

  4. Average daily Withdrawal Assessment Tool (WAT-1) score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.

  5. Minimum daily WAT-1 score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.

  6. Maximum daily WAT-1 score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ages 0 to <18 years at the time of enrollment.
  2. If < 6 months postnatal age, gestational age ≥ 35 weeks.
  3. Admitted to an intensive care unit.
  4. Planned or anticipated mechanically ventilation for ≥2 days.
  5. Require sedation to maintain mechanical ventilation per clinical judgment.
  6. No contraindication to receipt of fentanyl or dexmedetomidine per clinician judgment.
  7. Availability and willingness of the parent/legal guardian to provide written informed consent.

Exclusion Criteria:

  1. Previous participation in this study.
  2. Severe traumatic brain injury as the underlying etiology for critical illness requiring mechanical ventilation or baseline pediatric cerebral performance category (PCPC) >3.
  3. Planned receipt of sedatives other than fentanyl or dexmedetomidine.
  4. Anticipated receipt of neuromuscular blockade for >48 consecutive hours during the study period.
  5. Receipt of fentanyl or dexmedetomidine via continuous infusion for >12 hours in the 24 hours prior to enrollment.
  6. Extracorporeal life support (including renal replacement therapy, extracorporeal membrane oxygenation, ventricular assist device, etc.) at the time of enrollment.
  7. Chronic use of or recent overdose of serotonergic agents (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase (MAO) inhibitors, cyclic antidepressants)
  8. Known pregnancy
  9. Known liver dysfunction, defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2x the upper limit of normal for age
  10. Known or impending renal failure defined as: anuria > or equal to 12 hours prior to enrollment or requiring renal replacement therapy
  11. High risk children, define as: a. known heart block b. known bradyarrythmia including clinically significant bradycardia (defined as requiring chronotropic agents or cardiac pacing to treat)
  12. Receipt of mechanical ventilation during an admission for cardiac surgery

Note: receipt of drugs other than fentanyl or dexmedetomidine for intubation, and receipt of neuromuscular blockage for intubation, will not be considered exclusionary criteria.

Contacts and Locations

Locations
Show Show 19 study locations
Sponsors and Collaborators
Duke University
National Institutes of Health (NIH)
Johns Hopkins University
Intermountain Health Care, Inc.
Vanderbilt University Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Daniel Benjamin, MD Duke Clinical Research Institute
Tracking Information
First Submitted Date  ICMJE April 25, 2019
First Posted Date  ICMJE May 6, 2019
Last Update Posted Date February 9, 2021
Actual Study Start Date  ICMJE July 18, 2019
Actual Primary Completion Date October 21, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 2, 2019)
Mean daily dose of fentanyl in mcg/kg [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
Characterize the opioid-sparing effect of dexmedetomidine when co-administered with fentanyl in children receiving mechanical ventilation. Characterization of differences between dosing exposures for the four groups will allow estimation of the opioid-sparing effect of dexmedetomidine.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 2, 2019)
  • Sedation based on the State Behavior Scale (SBS) relative to Fentanyl plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Fentanyl plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Fentanyl plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Fentanyl plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on SBS scale relative to Dexmedetomidine plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The SBS is a 6-point scale that ranges from +2 to -3 with -3. Scores that are more negative reflect a more sedated state (-3). Scores that are more positive reflect a more agitated state (+2). Zero is awake and easily calmed.
  • Sedation based on Richmond Agitation and Sedation Scale (RASS) scale relative to Fentanyl plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Fentanyl plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-pint scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Fentanyl plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Fentanyl plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Cmax) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Cmin) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (Css) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Sedation based on RASS scale relative to Dexmedetomidine plasma concentrations (AUC) [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Characterize the exposure response relationships of fentanyl and dexmedetomidine when administered alone or in combination in children receiving mechanical ventilation. PK is known to be altered in children compared to adults, and in those with critical illness. Characterization of pharmacokinetic-pharmacodynamic relationships can improve dose optimization when dose may not be equivalent to plasma exposure and related effect. The RASS scale is a 10-point scale that ranges from -5 to +4 with -5=unarousable and +4=combative. Zero means the patient is alert and calm.
  • Incidence of SAEs in subjects [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).
  • Number of clinically significant episodes of hypotension [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).
  • Number of clinically significant episodes of bradycardia [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).
  • Number of clinically significant episodes of urinary retention [ Time Frame: up to 28 days or until discharge from the ICU (whichever is first) ]
    Characterize the safety profile of fentanyl and dexmedetomidine when administered alone or in combination to children receiving mechanical ventilation. (Safety measure).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: May 2, 2019)
  • Average daily Cornell Assessment of Pediatrics in Delirium (CAPD) scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.
  • Maximum daily CAPD scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.
  • Minimum daily CAPD scores [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of intensive care unit delirium in children exposed to fentanyl and dexmedetomidine alone or in combination when receiving mechanical ventilation. (Measures of delirium). The CAPD scale goes from 0-4 and has 8 questions. All items scored as occurring never, rarely, sometimes, often, or always. Individual item scores are added for a sum total score.
  • Average daily Withdrawal Assessment Tool (WAT-1) score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.
  • Minimum daily WAT-1 score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.
  • Maximum daily WAT-1 score [ Time Frame: through day 7 of mechanical ventilation or initial extubation (whichever is first) ]
    Estimate the incidence of opioid withdrawal syndrome in children exposed to fentanyl and dexmedetomidine when administered alone or in combination when receiving mechanical ventilation. (Measures of withdrawal). WAT-1 scale is 0=no/none and 1=yes/moderate/severe. Total score is on a 0-12 scale where lower is better.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE DOSE Trial of Opioid Sparing Effect
Official Title  ICMJE DEXMEDETOMIDINE OPIOID SPARING EFFECT IN MECHANICALLY VENTILATED CHILDREN: Phase 1b, Multicenter, Double Blind Randomized Controlled Dose Escalating Trial of Fentanyl vs. Fentanyl + Dexmedetomidine as the Initial Regimen for Maintenance of Sedation in Mechanically-ventilated, Critically Ill Children
Brief Summary

Multicenter, double blind randomized controlled trial of fentanyl vs. fentanyl + dexmedetomidine as the initial regimen for maintenance of sedation in mechanically-ventilated, critically ill children.

This trial will evaluate the opioid-sparing effect of dexmedetomidine when administered with fentanyl to mechanically ventilated, critically ill children. Study drug or placebo will be administered with fentanyl, which will be titrated to achieve sedation scores consistent with response to light touch. Plasma samples and bedside assessments for pain, sedation, and delirium will be collected.

Detailed Description

Phase 1b randomized, double-blind, placebo-controlled dose escalation trial of sedation regimens in critically ill children. Testing the hypothesis of mean daily fentanyl dose through day 7 of mechanical ventilation will be reduced by ≥25% by the addition of dexmedetomidine to fentanyl therapy. This trial will involve multiple clinical sites. Randomization will occur by individual and investigators will be blinded to study/treatment arm. The statistical analysis will account for center effects, participant characteristics (including post-surgical state), and changes over time to minimize bias. In addition, PIs and study coordinators will undergo training to standardize assessment procedures. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); and, Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).

An interim analysis is planned for this trial.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:
Phase 1b randomized, double-blind, placebo-controlled dose escalation trial. The study will randomize participants to receive placebo (fentanyl standard of care) titrated to sedation+saline placebo (bolus+infusion) or one of the following 3 Dexmedetomidine treatment arms in a sequential cohort fashion: Cohort 1: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2 mcg/kg/hr infusion); Cohort 2: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion); Cohort 3: Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion).
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Dexmedetomidine
  • Mechanical Ventilation Complication
  • Critically Ill
Intervention  ICMJE
  • Drug: Fentanyl
    Fentanyl standard of care
  • Drug: Dexmedetomidine
    Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
  • Drug: Dexmedetomidine
    Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
  • Drug: Dexmedetomidine
    Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
Study Arms  ICMJE
  • Placebo Comparator: Fen. SOC+saline placebo (bolus+infusion)
    Fentanyl standard of care (SOC) titrated to sedation + saline placebo (bolus + infusion)
    Intervention: Drug: Fentanyl
  • Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr)
    Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.2mcg/kg/hr infusion)
    Interventions:
    • Drug: Fentanyl
    • Drug: Dexmedetomidine
  • Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .5mcg/kg/hr)
    Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.5mcg/kg/hr infusion)
    Interventions:
    • Drug: Fentanyl
    • Drug: Dexmedetomidine
  • Active Comparator: Fen. SOC+Dex.(.5mcg/kg + .75mcg/kg/hr)
    Fentanyl SOC titrated to sedation + Dexmedetomidine (0.5mcg/kg bolus load + 0.7mcg/kg/hr infusion)
    Interventions:
    • Drug: Fentanyl
    • Drug: Dexmedetomidine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: February 4, 2021)
31
Original Estimated Enrollment  ICMJE
 (submitted: May 2, 2019)
48
Actual Study Completion Date  ICMJE November 6, 2020
Actual Primary Completion Date October 21, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Ages 0 to <18 years at the time of enrollment.
  2. If < 6 months postnatal age, gestational age ≥ 35 weeks.
  3. Admitted to an intensive care unit.
  4. Planned or anticipated mechanically ventilation for ≥2 days.
  5. Require sedation to maintain mechanical ventilation per clinical judgment.
  6. No contraindication to receipt of fentanyl or dexmedetomidine per clinician judgment.
  7. Availability and willingness of the parent/legal guardian to provide written informed consent.

Exclusion Criteria:

  1. Previous participation in this study.
  2. Severe traumatic brain injury as the underlying etiology for critical illness requiring mechanical ventilation or baseline pediatric cerebral performance category (PCPC) >3.
  3. Planned receipt of sedatives other than fentanyl or dexmedetomidine.
  4. Anticipated receipt of neuromuscular blockade for >48 consecutive hours during the study period.
  5. Receipt of fentanyl or dexmedetomidine via continuous infusion for >12 hours in the 24 hours prior to enrollment.
  6. Extracorporeal life support (including renal replacement therapy, extracorporeal membrane oxygenation, ventricular assist device, etc.) at the time of enrollment.
  7. Chronic use of or recent overdose of serotonergic agents (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase (MAO) inhibitors, cyclic antidepressants)
  8. Known pregnancy
  9. Known liver dysfunction, defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2x the upper limit of normal for age
  10. Known or impending renal failure defined as: anuria > or equal to 12 hours prior to enrollment or requiring renal replacement therapy
  11. High risk children, define as: a. known heart block b. known bradyarrythmia including clinically significant bradycardia (defined as requiring chronotropic agents or cardiac pacing to treat)
  12. Receipt of mechanical ventilation during an admission for cardiac surgery

Note: receipt of drugs other than fentanyl or dexmedetomidine for intubation, and receipt of neuromuscular blockage for intubation, will not be considered exclusionary criteria.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03938857
Other Study ID Numbers  ICMJE Pro00102267
5U24TR001608 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Duke University
Study Sponsor  ICMJE Duke University
Collaborators  ICMJE
  • National Institutes of Health (NIH)
  • Johns Hopkins University
  • Intermountain Health Care, Inc.
  • Vanderbilt University Medical Center
Investigators  ICMJE
Principal Investigator: Daniel Benjamin, MD Duke Clinical Research Institute
PRS Account Duke University
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP